Resources for Food and Drug Administration (FDA)

FDA declines to comment on motion against Ranbaxy

www.ptinews.com

The United States Food and Drug Administration today refused to comment on a motion filed by the Department of Justice in a US District Court in Maryland against Indian drug major Ranbaxy Pharmaceuticals.
"We do not comment on an ongoing litigation," an FDA spokesperson at Rockville, Maryland, told PTI when reached over phone.

The Federal prosecutors are investigating if the Indian generic drugmaker falsified records that resulted in the production of generic drugs that did not meet the standards of the FDA.

A comment from Ranbaxy's communications chief Chuck Caprariello was not immediately available.

The Star Ledger of New Jersey reported that authorities were alleging that Ranbaxys plant in northern India used raw chemicals from unapproved sources, fabricated in-house test data to meet FDA standards and attempted to conceal the ruse from FDA inspectors.

View the Resource

Share or bookmarklet this web page at: